Long
INFI BUY/LONG NOW READY! 3.00 to 8.35 by End 2021!
TICKER CODE: INFI
Company Name: INFINITY PHARMACEUTICALS, INC
US Stocks Health Technology Biotechnology
Position Proposed: BUY
FOMO BUY ENTRY: NOW READY (3.30)
NEXT BUY ENTRY: (3.00)
1st Partial Take Profit: 6.20 (July - August 2021)
2nd Partial Take Profit: 8.35 (End 2021)
NOTE THAT THE TIMELINE IS ONLY AN ESTIMATION
Stop Loss: 2.55
Technical Analysis
1. LARGE INVERTED HEAD & SHOULDERS PATTERN (Forming 2nd Shoulder)
2. Area of Confluence on EMA & structure level
3. Fibonacci Retracement at 0.786
4. 1st Partial Take Profit is at Fibonacci Extension Level 1 Grey Zone (Safe Zone) - This take profit is also at Key Level
5. 2nd Partial Take Profit will be at level 2 of Fibonacci Expansion Blue Zone.
6. 2nd Take Profit will be in the same price range as the Flagpole as well as 80% of the Head Price Range
Note that there might NOT be a RETEST FOR A RE-BUY ENTRY
Company Name: INFINITY PHARMACEUTICALS, INC
US Stocks Health Technology Biotechnology
Position Proposed: BUY
FOMO BUY ENTRY: NOW READY (3.30)
NEXT BUY ENTRY: (3.00)
1st Partial Take Profit: 6.20 (July - August 2021)
2nd Partial Take Profit: 8.35 (End 2021)
NOTE THAT THE TIMELINE IS ONLY AN ESTIMATION
Stop Loss: 2.55
Technical Analysis
1. LARGE INVERTED HEAD & SHOULDERS PATTERN (Forming 2nd Shoulder)
2. Area of Confluence on EMA & structure level
3. Fibonacci Retracement at 0.786
4. 1st Partial Take Profit is at Fibonacci Extension Level 1 Grey Zone (Safe Zone) - This take profit is also at Key Level
5. 2nd Partial Take Profit will be at level 2 of Fibonacci Expansion Blue Zone.
6. 2nd Take Profit will be in the same price range as the Flagpole as well as 80% of the Head Price Range
Note that there might NOT be a RETEST FOR A RE-BUY ENTRY
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.